X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Dasynoc (dasatinib) is an amorphous solid dispersion form & innovative protein kinase inhibitor, small molecule drug. It is being developed for the treatment of chronic myeloid leukemia.
Lead Product(s): Dasatinib
Therapeutic Area: Oncology Product Name: Dasynoc
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
Under the agreement, EVERSANA will support the U.S. launch and commercialization of the company's first innovative cancer therapy Dasynoc (dasatinib) for the treatment of chronic myeloid leukemia (CML) and acute lymphatic leukemia (ALL).
Lead Product(s): Dasatinib
Therapeutic Area: Oncology Product Name: Dasynoc
Highest Development Status: Phase IIIProduct Type: Small molecule
Recipient: Eversana
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement February 24, 2023
Details:
Xspray Pharma has received positive preliminary results from a bioavailability study in healthy volunteers with an improved HyNap-Dasa version of the reference drug Sprycel™, demonstrating that absorption of HyNap-Dasa is not dependent on the gastric pH level.
Lead Product(s): Dasatinib
Therapeutic Area: Oncology Product Name: HyNap-Dasa
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
